NSE filing, NSE: STAR. Summary written from the filing by ALFA Finder's alert engine.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,085.60
- Market cap
- ₹10,006 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.3×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Other other announcement announcements
All →ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.